Best Semaglutide Without Insurance in 2026: 7 Providers Ranked by Real Cost

← Best Semaglutide Online (full ranking) · Semaglutide hub · GLP-1 hub

The gap between the cheapest legitimate compounded semaglutide (Peak Wellness at $149/mo on the 12-month plan, $1,788/yr) and brand Wegovy at retail ($1,349/mo, $16,188/yr) is more than $14,000 a year. Same active ingredient. Different pricing tier.

If you are shopping for the best semaglutide without insurance, three legitimate tiers exist in April 2026. Tier 1 is compounded telehealth ($129 to $229/mo) from licensed 503A pharmacies under documented clinical justification. Tier 2 is NovoCare Pharmacy, Novo Nordisk’s direct-to-patient program for FDA-approved Wegovy ($199 intro, $349 ongoing) and Ozempic ($349 to $499/mo). Tier 3 is brand retail with tactics: GoodRx, savings cards, and the NovoCare Patient Assistance Program shipping free medication to income-qualified uninsured patients. Compounded saves 78 to 90% versus brand retail; NovoCare saves 63 to 85%.

This article ranks picks inside each tier. Peak Wellness leads Tier 1 at $149/mo annual, flat across every dose. Henry Meds follows at $119 with oral drops and dissolvable tablets. NovoCare owns Tier 2 with a Medicare and Medicaid exclusion competitors gloss over. We also name five providers to skip, give a seven-step pharmacy verification checklist, and cover the appeal playbook. For cross-molecule math, see our tirzepatide vs semaglutide breakdown and the sibling best tirzepatide without insurance guide.

One legal note. The FDA ended the semaglutide shortage on February 21, 2025; 503A pharmacies had until April 22, 2025 to wind down “essentially a copy” compounding, 503B facilities until May 22, 2025. Any provider claiming “FDA-approved compounded semaglutide” is lying; the FDA does not approve compounded drugs as finished products.

The Three Tiers: A Full Price Comparison Before You Pick

Most readers assume “compounded” means cheap and sketchy, “brand-name” means expensive but safe. After the FDA’s April 2025 and April 2026 compounding clarifications, the tier lines moved. Here is the honest map.

Tier 1: Compounded telehealth ($129 to $229/mo). State-licensed 503A pharmacies prepare personalized formulations to a prescriber’s individualized spec. Legal only with documented clinical justification (allergy to an inactive ingredient, required dose not commercially available, injection intolerance driving an oral format). Not FDA-approved as a finished product.

Tier 2: NovoCare Pharmacy self-pay ($199 intro to $499/mo). Novo Nordisk’s direct-to-patient program, launched March 2025. Ships FDA-approved Wegovy and Ozempic from the manufacturer’s pharmacy at rates far below retail. Medicare and Medicaid beneficiaries are excluded by federal anti-kickback law even if paying cash.

Tier 3: Brand retail pens ($1,027 to $1,400/mo list) with tactics. GoodRx trims Ozempic to roughly $900 to $1,000 at Costco. The Wegovy savings card covers $25/fill only for commercially insured patients. NovoCare’s Patient Assistance Program delivers free medication to uninsured patients at or below 400% of the federal poverty level.

Starting with Tier 1, here are the compounded telehealth picks.

1. Peak Wellness at $129 to $165 Flat

$129/mo month-to-month, no commitment. $165/mo on the 6-month plan. $149/mo on the 12-month plan. Same price whether you start at 0.25 mg or maintain at 2.4 mg.

Peak Wellness leads Tier 1 because the flat-rate structure eliminates the dose-tier surprise that catches readers off guard at competitors. The 6-month plan works out to $990 total paid upfront (two months free versus monthly). The 12-month plan is $1,788 billed annually. Cash-pay only, no insurance billing. Compounded semaglutide sourced from a state-licensed 503A pharmacy with documented clinical justification captured during intake.

What is included: physician review in under 4 hours, medication, syringes, free expedited shipping, and ongoing messaging with clinical staff. No membership fee. No consultation surcharge. No separate lab charge. No upcharge when you titrate.

The 12-month math is the persuasive part. At $149/mo annual, you pay $1,788 for a full year. Retail Wegovy at $1,349/mo is $16,188. That is $14,400 in your pocket on the same active ingredient. Versus Tier 2 NovoCare at $349/mo ongoing, Peak saves $2,400/yr. Versus Mochi’s $257/mo all-in, Peak saves $1,296/yr.

For perimenopausal readers, Peak’s clinical team documents hormone status during intake. Mayo Clinic research cited by menopause specialist Dr. Mary Claire Haver found roughly 30% greater weight loss in postmenopausal women who combined semaglutide with hormone therapy versus semaglutide alone. Peak does not prescribe HRT directly, but intake flags the synergy so your prescriber can coordinate.

Trade-offs we will name directly. Compounded semaglutide is not FDA-approved as a finished product. The 6-month plan locks in $990 upfront with a no-refund-once-shipped policy. Support is email-first, not live phone.

Best for: anyone planning to titrate past 0.5 mg who does not want their price to move with them. Skip if: you need live phone support, you are on Medicare or Medicaid, or you want FDA-approved brand specifically.

2. Henry Meds at $119 With Oral and Injection Options

From $119/mo starter pricing, available in three formats: weekly subcutaneous injection, oral drops, or dissolvable tablets. The oral options may qualify as legitimate 503A personalized formulations without stretching the FDA’s April 2026 B12-combination clarification.

Henry Meds owns the lowest advertised starting price in compounded telehealth. Pricing begins at $119/mo and climbs to roughly $149/mo at maintenance, tied with Ro Body on ongoing medication cost (before Ro’s $145 membership). No membership fee. Partners exclusively with licensed US compounding pharmacies under 503A oversight.

Format flexibility is the real differentiator. Oral drops (sublingual) and dissolvable tablets are rare in compounded semaglutide and give a provider legitimate clinical ground for 503A personalization: a patient who cannot self-inject, or who has documented swallowing difficulty. Those are real personalized formulations, not “essentially a copy” of the branded injectable. That matters more in April 2026 than any prior year, because the FDA’s April 1, 2026 clarification specifically flagged semaglutide plus B12 combinations as potentially still “essentially a copy” absent robust individualized clinical justification.

Trade-offs. Oral drops have a different absorption profile than subcutaneous injection, and dose equivalence is not 1:1, so your prescriber will set a different titration schedule. No specific menopause-trained clinical track. Provider communication is asynchronous; no live video visit at the base price.

Who it fits: needle-averse patients, readers chasing the absolute lowest starting price, and readers who want sublingual dosing.

Henry Meds beats Peak Wellness on starting price by $10/mo and beats every platform on format flexibility. Peak still wins on flat-rate maintenance (no jump from $119 to $149 as you titrate) and hormone-aware intake.

3. Eden With Published Pricing and a 3-Month Lock

Eden publishes a month-by-month price table on its homepage, which almost no compounded telehealth provider does. No “starting at” fine print. What you see at the top of the funnel is what you pay.

Pricing is $149 first month and $229/mo ongoing on the monthly plan. The 3-month plan is $129 first month and $209/mo ongoing, saving roughly $20/mo once you are past intro. No separate membership fee. Included: licensed provider visit, medication from a 503A partner pharmacy, shipping.

Transparency is the real pitch. Most compounded platforms require you to complete intake before a price appears on screen, which makes honest cross-shopping hard for uninsured readers trying to budget in advance. Eden breaks that pattern. If you do not want to hand over medical history just to see a number, Eden’s funnel respects that.

Trade-offs. Ongoing price is higher than Peak Wellness ($229 versus $165 on the 6-month plan) and higher than Henry Meds maintenance (~$149). Eden is also a content competitor for this keyword, which means its own blog reviews lean promotional; verify the pharmacy partner independently with the NABP tools below. Not FDA-approved compounded product.

Who it fits: first-time GLP-1 buyers who want to see the price before handing over medical history, and readers who want a 3-month trial window before a 6-month or annual commitment somewhere else.

Best for: readers who prioritize published-price transparency over rock-bottom rate. Skip if: you want the lowest possible monthly rate, or you are already committed to a longer plan elsewhere.

4. Mochi Health With Bundled Dietitian and Video Visits

Most compounded telehealth is async messaging with a prescriber you never see. If nausea is bad at week two or dose titration feels off, you are on your own. Mochi bundles actual 1-on-1 video visits and a registered dietitian into a flat structure, but you need to count both lines on the bill.

Pricing: $178/mo medication plus $79/mo membership. All-in: $257/mo, or $3,084/yr. Higher than Peak, Henry, and Eden ongoing, but lower than Tier 2 NovoCare at $349/mo for Wegovy injection maintenance.

What is bundled: video visits with licensed providers, dedicated registered dietitian access, medication management, and continuous clinical support through the platform. That is real clinical work, not a portal you message once a month.

Where it earns the higher price: patients with moderate comorbidities who would otherwise pay a primary-care copay plus a dietitian copay separately; perimenopausal patients who want a structured GLP-1-plus-nutrition conversation; readers who have tried async telehealth and know they need more touchpoints.

Trade-offs. The $79 membership is a separate subscription line. Mochi discloses it openly, but the structure mimics the dual-subscription model flagged in the blacklist section below, so budget-conscious readers should know. Not FDA-approved. The ~$100/mo premium over Peak Wellness annual adds up to $1,296/yr.

Mochi is the right pick when you would otherwise pay separately for a provider visit and a dietitian. If you just want a prescription shipped, Peak or Henry is cheaper and simpler.

5. Runners-Up: Ro Body, Hers, Invigor Medical, and Fridays

Four more compounded options worth knowing about before you commit. Each has a specific use case, and one is pivoting from compounded to branded under a Novo Nordisk partnership in 2026.

Ro Body Program ($149/mo medication + $145/mo Ro Body membership = ~$294/mo all-in). Medication cost ties Henry Meds on the low end, but the mandatory membership doubles the all-in rate. Coaching is included in the membership. Best for: patients who specifically want Ro’s coaching structure. Skip if: you do not want a second subscription line.

Hims & Hers (Hers) ($199/mo, pivoting to branded Wegovy in March 2026). Announced a Novo Nordisk partnership adding FDA-approved Wegovy alongside compounded. Subject to September 2025 FDA warning letters, a Novo Nordisk patent infringement lawsuit filed February 9, 2026 alleging “inauthentic API,” and 500+ BBB complaints citing billing disputes and a 48-hour cancellation window. Best for: readers tracking the branded pivot. Skip if: you need refund flexibility.

Invigor Medical. Established telehealth with compounded semaglutide; pricing typically $219 to $249/mo. Medical-office heritage rather than pure DTC, appealing to readers who want a more clinical-feeling intake.

Fridays. Bundled flat-rate model (coaching, dietitian, medication), roughly $240 to $359/mo depending on plan length. BBB complaints about shipping delays are documented. Best for: readers who want bundled coaching without Ro’s separate membership line. Verify shipping turnaround before committing.

Ro and Hers have name recognition the top four do not. They also have dual-subscription structures and BBB complaint histories the top four do not. Pick from the ranked four above unless you have a specific reason to prefer one of these.

6. The NovoCare Pharmacy Playbook for Self-Pay Wegovy and Ozempic

Novo Nordisk launched NovoCare Pharmacy in March 2025 and dropped brand Wegovy from about $1,349 retail to $499/mo. In November 2025 they dropped it again to $349/mo ongoing. Zero of the competitors ranking for “best semaglutide without insurance” walk through the full price ladder. If you are on Medicare or Medicaid, you are blocked from this program even if you want to pay cash.

Full NovoCare price ladder (April 2026):

• Wegovy injection starter (0.25 mg and 0.5 mg, first 2 fills through June 30, 2026): $199/mo
• Wegovy injection ongoing (0.5 mg through 2.4 mg maintenance): $349/mo
• Wegovy oral pill starter (1.5 mg, and 4 mg through August 31, 2026): $149/mo
• Wegovy oral pill (7 mg and 14 mg): $199/mo after the 4 mg promo ends
• Wegovy oral pill maintenance (25 mg): $299/mo
• Ozempic (0.25 mg, 0.5 mg, 1 mg): $349/mo
• Ozempic (2 mg): $499/mo

Step-by-step enrollment:

1. Confirm you are not on Medicare, Medicaid, TRICARE, or any government insurance program. Federal anti-kickback law bars you from NovoCare pricing even if you pay cash.
2. Get a prescription specifically for Wegovy or Ozempic, not for compounded semaglutide. An existing compound Rx is not transferable.
3. Text SAVE to 83757 for the digital savings offer, or call NovoCare at 1-888-793-1218 (Mon-Fri, 8 am to 8 pm ET).
4. Complete enrollment at novocare.com/pharmacy.html.
5. Home delivery with free shipping.
6. At each refill, confirm current pricing. NovoCare has adjusted pricing multiple times since launch (it was $499 at launch, $349 by November 2025).

What you trade for FDA approval: no insurance billing, no GoodRx or Wegovy savings card stacking, Medicare and Medicaid excluded, and the Rx must be written specifically for Wegovy or Ozempic rather than a compound your current provider may have on file.

When NovoCare beats compounded: you want FDA-approved product specifically; you cannot find a provider willing to document 503A clinical justification; you are at Wegovy starter doses where $199/mo intro beats some compounded maintenance tiers; or you want direct manufacturer supply chain.

When compounded beats NovoCare: you are on Medicare or Medicaid (blocked entirely); you want the lowest monthly price (Peak Wellness at $149/mo annual is cheaper than NovoCare’s $199 intro and less than half of $349 ongoing); or you need a format NovoCare does not offer (custom dose, sublingual drops).

NovoCare is the cheapest legitimate brand-name path for any uninsured shopper not on Medicare or Medicaid. Medicare and Medicaid patients: skip to the NovoCare Patient Assistance Program below.

7. GoodRx, Savings Cards, and the Free-Medication PAP Path

Novo Nordisk runs a patient assistance program that provides Wegovy, Ozempic, and Rybelsus at no cost to uninsured patients with household income at or below 400% of the federal poverty level. Not one of the top three competitors ranking for this query mentions it. For the lowest-income segment of the uninsured market, it is the single most important path in this guide.

GoodRx and SingleCare (brand pens only). Wegovy retail runs about $1,349/mo; GoodRx lands it around $1,200/mo at Costco, still far above NovoCare’s $349. Ozempic retail is about $1,027/mo; GoodRx drops it to roughly $900/mo at Costco, consistently $50 to $100 cheaper than CVS or Walgreens in the same zip. For Ozempic starter doses, GoodRx can match NovoCare’s $199 first-two-fill pricing at participating pharmacies. Use this path only if you cannot move your prescription to NovoCare.

Wegovy savings card (commercially insured only). $25/fill for patients with commercial insurance covering Wegovy. Does NOT apply to uninsured patients. Does NOT stack with NovoCare pricing. If your commercial plan denies Wegovy, the savings card may still work through retail while you appeal.

Ozempic savings card (Type 2 diabetes only). Requires a T2D diagnosis on the prescription. Off-label weight-loss prescriptions are not eligible. Apply at ozempic.com/savings.

Walgreens Weight Management Program. Wegovy as low as $149/mo for the first two months through August 31, 2026 for self-pay patients. Retail-telehealth hybrid priced similarly to NovoCare’s intro. Compare pharmacy convenience against NovoCare’s home delivery.

NovoCare Patient Assistance Program (PAP) for uninsured at or below 400% FPL. Wegovy, Ozempic, and Rybelsus at no cost to qualifying patients. Requires application and income verification at novocare.com/patient. This is the zero-cost path for readers who cannot afford even NovoCare’s $199 starter rate.

Skip GoodRx for Wegovy unless you are locked into a pen prescription. Use it for Ozempic only if your script is coded for T2D. Apply for NovoCare PAP first if your household income is at or below 400% FPL. Free medication beats every other option on this list.

Providers to Avoid: Why Uninsured Shoppers Are Especially Vulnerable

These five names will come up when you Google “semaglutide online.” They look affordable at intro price. Uninsured shoppers are the most exposed to their hidden fees because there is no insurance billing department to catch duplicate charges or flag a disputed line item.

Hims & Hers (Hers). $199/mo compounded base, $149 on some tiers. True all-in runs higher after BBB-flagged billing disputes and a strict 48-hour cancellation window. September 2025 FDA warning letters for misleading compounded-versus-FDA-approved marketing. Novo Nordisk patent infringement lawsuit February 9, 2026 alleging “inauthentic API.” 500+ BBB complaints over three years. Even with the March 2026 branded-Wegovy pivot, active litigation risk remains.

Mochi Health (for readers who do not need bundled support). $178/mo medication plus a separate $79/mo membership, billed as two distinct subscriptions. True all-in: $257/mo. Mochi discloses this openly, but readers who came here for the lowest monthly price should know the membership doubles your cost base relative to Peak or Henry.

SkinnyRx. PolicyLab flagged this platform for bundle offers that obscure the true per-month rate and a pattern of BBB complaints diverging sharply from Trustpilot reviews. Cross-check both databases, but especially here.

OnlineSemaglutide.org. PolicyLab documents $80 consultation fees layered on top of advertised medication prices, plus shipping surcharges not quoted upfront. Avoid.

TrimRx-style billing platforms. Subscription-billing providers with documented cases of charges exceeding authorized amounts. The 2025 Consumer Reports telehealth survey found 34% of GLP-1 patients hit unexpected charges, and this category is the main reason.

Switching from Mochi ($257/mo all-in) to Peak Wellness ($149/mo annual) saves $1,296/yr. Switching from Hers ($199/mo with documented billing disputes) to Peak saves $600/yr plus the subscription risk. Those are rent-money numbers.

If a checkout flow shows two separate subscription lines, or if the provider refuses to name its compounding pharmacy partner by state license number, close the tab. For readers specifically shopping a no-membership model, our best compounded semaglutide breakdown and semaglutide no-membership shortlist cover that angle in depth.

How to Verify Any Compounded Pharmacy Before You Pay

Four minutes with this checklist can save you $100 to $600 in fees, subscription traps, or medication from a pharmacy under FDA investigation. The FDA has issued 85+ warning letters to compounded GLP-1 sellers since September 2025.

1. Name the pharmacy. Ask: “What is the full legal name and state pharmacy license number of your compounding partner?” A legitimate provider answers in one email. Refusal or vague answers are a hard no.
2. Check safe.pharmacy (NABP’s free tool). Enter the pharmacy URL. “Accredited” is pass; “NABP Not Recommended” is walk away. NABP has flagged 40,000+ non-compliant pharmacy websites.
3. Look for a .pharmacy domain extension. Issued and verified by NABP, cannot be forged. Not every legitimate pharmacy has one, but it is a strong positive signal.
4. Search LegitScript at legitscript.com. Verifies legal compliance and maps to 503A standards and consumer protection requirements.
5. Verify the state pharmacy license via nabp.pharmacy/boards-of-pharmacy/. Confirm an active license with no recent disciplinary actions.
6. Cross-check FDA warning letters at fda.gov. The FDA has issued 55+ warning letters to compounded GLP-1 sellers since September 2025, plus 30+ in March 2026, including one dated January 16, 2026 against Boothwyn Pharmacy LLC for insanitary conditions.
7. Confirm NABP Compounding Pharmacy Accreditation at nabp.pharmacy/programs/accreditations/compounding-pharmacy/. This is a separate credential specific to sterile-compounding standards.

Absolute red flags: “FDA-approved compounded” semaglutide claims (impossible), price below $90/mo (ingredient cost alone exceeds that), overseas shipping from China or India, no prescriber oversight, or refusal to name the partner pharmacy.

If a provider fails any of these seven checks, the savings are not worth it.

If You Have Insurance But the Plan Denied You: The Appeal Playbook

If your insurance denied Ozempic for weight loss, you have a 20 to 30% chance of winning an internal appeal and 40 to 50% on external review. If your employer explicitly excluded weight-loss drugs, appeal odds drop to near zero. Check your denial type first.

Step 1: identify the denial type from the Explanation of Benefits.

• Off-label (Ozempic for weight loss, non-diabetic): appealable with medical necessity documentation. 20 to 30% internal success. The most common denial, since Ozempic is FDA-approved only for type 2 diabetes.
• Medical necessity (Wegovy): appealable with clinical documentation. Higher success on external review.
• Plan exclusion: employer contract excluded anti-obesity drugs. Appeals almost never succeed; skip to NovoCare or compounded.
• Step therapy: provider must document failed prior therapies. Appealable with documentation in hand.

Step 2: request a Letter of Medical Necessity. Must include BMI 30+ (or 27+ with a comorbidity like hypertension, type 2 diabetes, dyslipidemia, or sleep apnea), documented failed diet and exercise, and cardiovascular or metabolic risk. For Wegovy, cite the SELECT trial (20% reduction in major cardiovascular events) if applicable.

Step 3: file the internal appeal within the plan’s deadline (typically 60 days; confirm in your plan document).

Step 4: if denied, request an external independent medical review. Success jumps to 40 to 50%.

The Ozempic trap. Even if you win, Ozempic for weight loss is off-label and a later auditor can claw back approval. Wegovy is on-label. If your prescriber will switch to Wegovy, the appeal is cleaner.

Skip the appeal entirely if your denial cites plan exclusion, your employer opted out of weight-loss coverage, or you are a Medicare Part D beneficiary seeking Wegovy for weight loss alone. Move directly to NovoCare ($199 intro, $349 ongoing) or Peak Wellness ($129 to $165/mo). Medical necessity and step therapy denials are worth the effort; plan exclusions are not.

Frequently Asked Questions About Semaglutide Without Insurance

Is compounded semaglutide still legal in 2026?

Yes, but only under 503A personalized-formulation exceptions with documented patient-specific clinical justification. The FDA ended the semaglutide shortage on February 21, 2025; 503A pharmacies had until April 22, 2025 to wind down “essentially a copy” compounding. Per the FDA’s April 1, 2026 clarification, B12 add-ons do not qualify. You need a real clinical reason: allergy to an inactive ingredient, a dose not commercially available, or documented injection intolerance.

Can I get Ozempic without insurance?

Yes, through four paths. NovoCare Pharmacy self-pay at $349/mo (0.25 to 1 mg) or $499/mo (2 mg). GoodRx at Costco for $900 to $1,000/mo, sometimes $199 for the first two fills. Compounded semaglutide via 503A telehealth at $129 to $229/mo. NovoCare’s Patient Assistance Program, free for uninsured at or below 400% FPL. Ozempic is FDA-approved only for type 2 diabetes, so weight-loss prescriptions are off-label and almost always denied.

What is NovoCare Pharmacy?

Novo Nordisk’s direct-to-patient home delivery program, launched March 2025. Self-pay rates: Wegovy $199/mo intro or $349/mo ongoing; Ozempic $349 to $499/mo. Enroll by texting SAVE to 83757 or calling 1-888-793-1218. Medicare, Medicaid, and TRICARE patients are excluded under federal anti-kickback law even if paying cash.

Is Rybelsus cheaper than injections without insurance?

Not at retail. Rybelsus list price is about $997.58/mo; GoodRx trims roughly 25% to $750/mo. For a cheaper oral, NovoCare offers FDA-approved oral Wegovy at $149/mo for 1.5 mg and 4 mg starters (through August 31, 2026), $199/mo for 7 or 14 mg, and $299/mo for 25 mg. Rybelsus is approved only for type 2 diabetes; oral Wegovy is approved for weight loss.

Does GoodRx actually bring Wegovy under $500?

No, not reliably. GoodRx typically lands Wegovy at $1,200 to $1,349/mo at Costco; the floor with coupon-stacking is around $900/mo. NovoCare is the path below $500: $199 intro or $349 ongoing. GoodRx and NovoCare do not stack. For Ozempic, GoodRx at Costco can match NovoCare’s starter pricing.

Can I use my HSA or FSA to pay for semaglutide without insurance?

Yes. Peak Wellness, Henry Meds, and Eden accept HSA or FSA reimbursement. NovoCare accepts HSA and FSA for Wegovy and Ozempic self-pay. GoodRx coupons pair with HSA or FSA at retail. Save receipts; most administrators require documentation showing medication name, date, and amount paid.